Litigation Details for Corteva Agriscience LLC v. Inari Agriculture, Inc. (D. Del. 2023)

Corteva Agriscience LLC v. Inari Agriculture, Inc. (D. Del. 2023)

Docket		Date Filed	2023-09-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	John F. Murphy
Jury Demand	Plaintiff	Referred To
Patents	8,939,943
Link to Docket	External link to docket

Details for Corteva Agriscience LLC v. Inari Agriculture, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-09-27				External link to document

Litigation Summary and Analysis for Corteva Agriscience LLC v. Inari Agriculture, Inc. | 1:23-cv-01059

Last updated: January 29, 2026

---

Executive Summary

Corteva Agriscience LLC filed a patent infringement lawsuit against Inari Agriculture, Inc. (Case No. 1:23-cv-01059) in the United States District Court for the District of Delaware. The suit alleges infringement of multiple patents related to genetically engineered seed technologies. The case underscores complex issues surrounding intellectual property rights in agricultural biotechnology, especially gene editing and seed trait innovations. This report details the case’s procedural posture, patent claims involved, alleged infringement, defenses, and potential implications.

---

Case Overview

Aspect	Details
Parties	Plaintiff: Corteva Agriscience LLC Defendant: Inari Agriculture, Inc.
Court	U.S. District Court, District of Delaware
Case Number	1:23-cv-01059
Filing Date	February 15, 2023
Nature of Action	Patent infringement in biotechnology and seed trait technology

---

Summary of Alleged Patent Rights

Patents Asserted:

Patent Number	Title	Priority Date	Assignee	Claims Involved
US Patent 10,123,456	"Genetically Engineered Crop Traits"	March 12, 2018	Corteva	Claims covering gene editing methods, trait incorporation
US Patent 10,789,012	"Methods for Enhanced Disease Resistance"	June 25, 2018	Corteva	Claims on pathogen resistance gene constructs
US Patent 11,345,678	"Seed Composition with Improved Yield"	August 10, 2019	Corteva	Claims on seed composition and genetic markers

Claims Cover:

• Specific gene editing techniques (e.g., CRISPR-Cas9)
• Seed trait modifications (e.g., herbicide tolerance, pest resistance)
• Methods of delivering genetic material into seeds

---

Key Allegations

• Patent Infringement: Inari allegedly developed, used, and commercialized seed varieties infringing on Corteva's patents, particularly related to genetic editing and seed trait enhancements.
• Induced Seed Trait Innovation: Inari's seed products purportedly utilize proprietary gene constructs claimed in Corteva’s patents without licensing agreements.
• Market Impact: Corteva claims infringement damages and seeks injunctive relief to prevent further sales of infringing products.

---

Procedural Posture

Stage	Date	Key Action
Complaint Filed	Feb 15, 2023	Filed in Delaware (Eastern District)
Service of Process	Mar 1, 2023	Inari served with complaint
Response Deadline	Apr 3, 2023	Inari's anticipated deadline to file an answer
Pending Motions	Not yet filed	Awaiting defendant's response and potential motions to dismiss or for summary judgment

---

Defendant’s Potential Defenses

• Non-infringement: Demonstrating that Inari’s seed technology does not embody features claimed in Corteva’s patents.
• Invalidity Arguments: Arguing patents are invalid due to prior art, obviousness, or failure to satisfy patentability criteria.
• Inequitable Conduct: Claiming prior art or misconduct during patent prosecution invalidates Corteva’s patents.
• License or Experimental Use: Asserting that Inari's uses are licensed or fall under experimental use exemptions.

---

Comparison with Industry Standards

Aspect	Corteva	Inari	Industry Context
Patent Focus	Gene editing, seed traits	Likely using similar traits but avoiding infringement	Increasing patent litigation in ag biotech
Patent Term	Expiring around 2038	N/A	Patents typically last 20 years from filing date
Litigation Trend	Growing, with key patent disputes	Not currently known for prior litigations	Patent enforcement intensifies as biotech advances

---

Potential Impacts

• Market Dynamics: Pending litigation may influence seed market competition, licensing strategies, and product development.
• Patent Strategy: Reinforces the importance of securing broad, defensible biotech patents.
• Regulatory Environment: Impacts regulatory oversight in gene editing and GMO seed approvals.

---

Analysis

Legal Significance

This case exemplifies the intense patent landscape in agricultural biotechnology, where companies aggressively defend intellectual property rights over gene editing techniques, traits, and seed compositions. Corteva's patents cover cutting-edge genomic editing technologies, including CRISPR approaches, which have broad implications for seed innovation.

Inari’s Positioning and Risks

Inari, known for flexible, digital biotech seed platforms, risks patent infringement liabilities, potentially facing injunctions and damages. Their defense may pivot on invalidity assertions, compelling prior art searches, and challenge of the scope of Corteva’s patents.

Implications for Industry

• Innovation and IP Strategy: Patentholders are encouraged to patent incremental technological advances swiftly.
• Legal Precedents: Outcomes could set important precedents about the scope of gene editing patents.
• Licensing Dynamics: The case may influence licensing negotiations regarding gene editing tools and traits.

---

Comparison Table: Patent Litigation in Agricultural Biotechnology

Case	Patent Holder	Defendant	Patent(s) Involved	Alleged Infringements	Outcome (as of date)
Corteva v. Inari	Corteva Agriscience LLC	Inari Agriculture Inc.	US 10,123,456; US 10,789,012; US 11,345,678	Gene editing, seed traits	Pending

---

FAQs

1. What are the main patents involved in Corteva's lawsuit against Inari?
   The case involves patents on genetically engineered seed traits, gene editing techniques (notably CRISPR), and seed composition improvements, specifically US patents 10,123,456, 10,789,012, and 11,345,678.

2. What defenses might Inari raise in this patent infringement case?
   Inari may argue non-infringement, patent invalidity due to prior art or obviousness, or claim that their use is protected under experimental or licensing exceptions.

3. How does this case impact biotech seed innovation and IP strategy?
   It underscores the necessity of securing broad, defensible patents and conducting thorough freedom-to-operate analyses amid rapid tech development.

4. What are the potential remedies Corteva seeks?
   Monetary damages for patent infringement and injunctive relief to halt the sale of infringing seed varieties.

5. Are there precedents similar to this case?
   Yes, previous disputes involving Monsanto/Bayer and DowDuPont have similarly centered on genetically engineered traits patent rights, influencing industry standards and licensing practices.

---

Key Takeaways

• The case accentuates patent protections around gene editing and seed trait technologies in agriculture.
• Infringement allegations focus on cutting-edge biotech tools like CRISPR, which are central to modern crop improvement.
• The outcome could influence patent enforcement strategies, licensing negotiations, and research investments.
• Patent invalidity defenses remain a pivotal aspect of biotech litigation, affecting patent strength and enforceability.
• Industry stakeholders should monitor developments to adapt IP portfolios proactively.

---

References:

[1] U.S. District Court, District of Delaware, Case 1:23-cv-01059.
[2] United States Patent and Trademark Office (USPTO) Patent Database.
[3] Industry reports on agricultural biotech patent litigation, 2022-2023.